Literature DB >> 18039107

Immunobiology and pathogenesis of viral hepatitis.

Luca G Guidotti1, Francis V Chisari.   

Abstract

Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV) and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause persistent infection, cirrhosis, and liver cancer. HBV and HCV are noncytopathic viruses and, thus, immunologically mediated events play an important role in the pathogenesis and outcome of these infections. The adaptive immune response mediates virtually all of the liver disease associated with viral hepatitis. However, it is becoming increasingly clear that antigen-nonspecific inflammatory cells exacerbate cytotoxic T lymphocyte (CTL)-induced immunopathology and that platelets enhance the accumulation of CTLs in the liver. Chronic hepatitis is characterized by an inefficient T cell response unable to completely clear HBV or HCV from the liver, which consequently sustains continuous cycles of low-level cell destruction. Over long periods of time, recurrent immune-mediated liver damage contributes to the development of cirrhosis and hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 18039107     DOI: 10.1146/annurev.pathol.1.110304.100230

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  291 in total

1.  Interleukin-1R signaling is essential for induction of proapoptotic CD8 T cells, viral clearance, and pathology during lymphocytic choriomeningitis virus infection in mice.

Authors:  Lars T Joeckel; Reinhard Wallich; Sunil S Metkar; Christopher J Froelich; Markus M Simon; Christoph Borner
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  NKT cells--an early warning system for HBV infection.

Authors:  Dale I Godfrey; Adam P Uldrich; Alan G Baxter
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 3.  Bioengineering in organ transplantation: targeting the liver.

Authors:  K Fukumitsu; H Yagi; A Soto-Gutierrez
Journal:  Transplant Proc       Date:  2011 Jul-Aug       Impact factor: 1.066

Review 4.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

5.  Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.

Authors:  Babita Agrawal; Rakesh Kumar
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

6.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

Review 7.  Technical standards for hepatitis B virus X protein (HBx) research.

Authors:  Betty L Slagle; Ourania M Andrisani; Michael J Bouchard; Caroline G L Lee; J-H James Ou; Aleem Siddiqui
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

8.  Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Authors:  Michael D Robek; Mayra L Garcia; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

Review 10.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.